Drug pricing and value in oncology

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Oncology

Background:

• Cancer drug pricing in the U.S. is a significant concern, with limited data on price relative to therapeutic value.
• Insurance coverage, patient cost-sharing, and reimbursement policies influence manufacturer pricing incentives.

Purpose of the Study:

• To analyze the factors influencing manufacturer pricing incentives for cancer drugs, focusing on insurance coverage and reimbursement.
• To examine the impact of patient cost-sharing, reimbursement rules for physician-dispensed drugs, and payer negotiation strategies on cancer drug prices.

Main Methods:

• Analysis of insurance coverage effects, including patient cost-sharing and specialty tier placement for pharmacy-dispensed drugs.
• Examination of reimbursement rules for physician-dispensed drugs, specifically Medicare's average selling price plus 6% rule.
• Simulation analysis of financial risks for Medicare Part D prescription drug plans (PDPs) regarding formulary placement.
• Review of international data (Canadian Common Drug Review) on cost-utility values for cancer drugs.

Main Results:

• Specialty tiers for pharmacy-dispensed cancer drugs limit discount negotiations and can lead to unaffordable patient cost-sharing.
• PDPs may be incentivized to place costly drugs on specialty tiers due to adverse selection risks.
• Medicare's reimbursement rule for physician-dispensed drugs favors higher-priced medications.
• International data suggests cancer drugs may be relatively high-priced compared to their utility, though U.S. data is lacking.

Conclusions:

• Current U.S. payer and regulatory structures create incentives for high cancer drug prices, potentially unlinked to value.
• Lack of outcomes-adjusted pricing data in the U.S. hinders the ability to assess and constrain cancer drug prices relative to value.
• Implementing value-based pricing assessments could help align cancer drug prices with their therapeutic benefits.